The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients

Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia (BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anastasia Putri, Ikhwan Rinaldi, Melva Louisa, Soekamto Koesnoe
Format:	Article
Language:	English
Published:	Interna Publishing 2020-02-01
Series:	Acta Medica Indonesiana
Subjects:	chronic Myeloid Leukemia STAT5 Imatinib tyrosine kinase inhibitor resistance
Online Access:	https://www.actamedindones.org/index.php/ijim/article/view/978
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Predicting Binding Affinity of Some Imatinib Derivatives as BCR-ABL Tyrosine Kinase Inhibitors Based on Monte Carlo Optimization
by: Shahram Lotfi, et al.
Published: (2024-09-01)

Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice
by: AG Turkina, et al.
Published: (2017-07-01)

Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC‐TFR Study
by: Hiroshi Ureshino, et al.
Published: (2025-08-01)

Investigation of the anti-cancer drugs imatinib and thalidomide using analytical spectroscopy (FT-IR, UV-Vis) and molecular docking simulations
by: P. Venkata Ramana, et al.
Published: (2025-07-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
by: Mohan Bajranglal Agarwal, et al.
Published: (2024-08-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad
by: Sandip A Shah
Published: (2013-01-01)

Research on the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia
by: Xiaoyun Feng, et al.
Published: (2025-05-01)

Large‐scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in Arabidopsis
by: Naoyuki Sugiyama, et al.
Published: (2008-05-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
by: Jovita Martin, et al.
Published: (2011-01-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-03-01)

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
by: Yaqi Zhou, et al.
Published: (2023-07-01)

Bilateral mandibular osteonecrosis associated with imatinib monotherapy for a patient with chronic myeloid leukemia
by: Yasuharu Yajima, et al.
Published: (2025-04-01)

Current trends in the treatment of recurrent adenocystic cancer of the salivary glands: case report
by: O. A. Saprina, et al.
Published: (2023-03-01)

Food interactions with tyrosine kinase inhibitors used to treat advanced renal cell carcinoma
by: Agata Sałek-Zań, et al.
Published: (2025-03-01)

The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases
by: Francesco D’Egidio, et al.
Published: (2025-07-01)

Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
by: Wulyo Rajabto, et al.
Published: (2023-01-01)

Bone Marrow and Kidney Findings at Odds: A Case Report and Review of Literature of Divergent Pathology in Chronic Myeloid Leukemia
by: Shivani Ranga, et al.

Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study
by: Ana Maria Meireles, et al.
Published: (2025-07-01)

Expression of arginase 1 and tyrosine kinase Mer by blood monocytes in the dynamics of physiological pregnancy
by: E. Ya. Shevela, et al.
Published: (2023-06-01)

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
by: Benjamin J. Lee, et al.
Published: (2024-10-01)

The inhibitory effect of tyrosine kinase inhibitors on angiogenesis in zebrafish and interrelationship with the activation of the PI3K/AKT pathway
by: Lili Yang, et al.
Published: (2025-08-01)

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
by: James W Peacock, et al.
Published: (2018-01-01)

The emerging role of Imatinib in malaria management: a review of evidence and future directions
by: Victor Oluwatomiwa Ajekiigbe, et al.
Published: (2025-08-01)

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
by: Tara Murty, et al.
Published: (2025-06-01)

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database
by: Zongwei Tang, et al.
Published: (2025-07-01)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025-08-01)

Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?
by: Hsiang-Wen Lin, et al.
Published: (2025-08-01)

Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
by: Ajibade Ashaye, et al.
Published: (2025-04-01)

Upregulation of ICAM-1 Expression on J774.2 Macrophages by Endotoxin Involves Activation of NF-κB but not Protein Tyrosine Kinase: Comparison to Induction of iNOS
by: Hartmut Ruetten, et al.
Published: (1999-01-01)

Characterization of a pathogenic gain-of-function mutation in the N-terminal domain of STAT1 which is reported to be associated with eosinophilic esophagitis
by: Kristin Annawald, et al.
Published: (2025-08-01)

Brain-derived neurotrophic factor and neurotrophic tyrosine receptor kinase-2 in stallion testes: insights into seasonal changes and potential roles in spermatogenesis
by: Muhammad Shakeel, et al.
Published: (2025-07-01)

Effect of functionalization on the adsorption performance of carbon nanotube as a drug delivery system for imatinib: molecular simulation study
by: Masume Rezazade, et al.
Published: (2024-04-01)

Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review
by: Vasile Gaborean, et al.
Published: (2025-06-01)

Iron overload promotes myeloid differentiation of normal hematopoietic stem cells and educates macrophage mediated immunosuppression in acute myeloid leukemia
by: Feifei Yang, et al.
Published: (2025-08-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)